Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Wednesday.
----------
AIM WINNERS
----------
Europa Oil & Gas, up 23% at 1.67 pence, 12-month range 0.55p-2.80p. The UK, Ireland and Morocco-focused oil and gas explorer has entered into a GBP225,000 unsecured loan facility with Non-Executive William Ahlefeldt. Europa said it decided to enter the loan facility in order to fund any possible cost overruns after the partners in the Wressle development elected to defer workover operations and final commissioning of the oil field to January 2021.
----------
Drumz, up 16% at 0.785p, 12-month range 0.40p-1.20p. The investment company focused on the software sector said investee Acuity Risk Management - in which Drumz holds a 20% stake with an option to acquire a further 5% - has launched a "significant" upgrade to its STREAM Integrated Risk Manager software product. Acuity's sales team believes the new features will "greatly increase" the appeal of STREAM to larger organisations.
----------
Faron Pharmaceuticals, up 13% at 390p, 12-month range 203.84p-595.00p. The biopharmaceutical company said latest scientific observations from the phase I/II MATINS clinical trial - which is investigating bexmarilimab, Faron's novel precision cancer immunotherapy targeting Clever-1, a receptor known to be expressed on immunosuppressive macrophages in the tumour microenvironment - include the identification of a new role for soluble Clever-1, related to its capacity to control T-cell activation. "This suggests that the inactivation of Clever-1 as an immune suppressive molecule could be even broader and more important than previously thought as the immune-stimulating effects are not only limited to tumour associated macrophages but may also act systemically," said Faron.
----------
Angle, up 11% at 72.19p, 12-month range 37.90p-78.00p. The liquid biopsy company said new data demonstrate the performance of its Parsotrix system versus the leading antibody-based CTC system. "We welcome the publication of this study by Professor Allan's group which further demonstrates the capabilities of the Parsortix system to harvest CTCs, irrespective of biomarker status. Furthermore, the Parsortix system provides access to viable tumour cells for downstream analysis making it an optimal platform for personalised medicine and for informing the development of targeted therapies," said Angle Founder & Chief Executive Andrew Newland.
----------
AIM LOSERS
----------
Sabien Technology, down 57% at 0.082p, 12-month range 0.050p-19.00p. Stock was readmitted to trading on AIM after being suspended last January. The energy efficiency technology firm said its acquisition of Ptarmigan Health Destinations will not be proceeding as it was not able to secure required Swiss and UK regulatory approvals in sufficient time to avoid the cancellation of its shares on AIM. "Whilst the board continues to believe the Proposed Acquisition was in the best interests of all shareholders, it decided to withdraw from discussions with Ptarmigan Health Destinations SA in order to maintain the admission of its ordinary shares to trading on AIM," said Sabien.
----------
Deltex Medical, down 9.7% at 1.76p, 12-month range 0.80p-2.90p. The medical devices manufacturer said revenue for 2020 was GBP2.4 million, down sharply on GBP4.3 million in 2019. The company said revenue in 2020 was "adversely affected" by Covid-19 and the associated significant reduction in elective surgical procedures worldwide.
----------
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.